Originally Published IVD Technology July/August 2002
Industry News
Partnership to develop proteomic chip technology
Metrigenix Inc. (Gaithersburg, MD) and Temple University (Philadelphia) are codeveloping proteomic chips for application in the area of cardiovascular disease. Temple University will provide a selection of proteins based on their relevance to congestive heart failure and Metrigenix will supply its flow-through biochips with antibodies to monitor the proteins using the company's 4D assay system.
"The 4D assay system should become an invaluable component to our research efforts because of its multitasking capability across both gene expression and protein expression in the same assay system," says Kenneth Margulies, MD, of Temple University.
The 4D assay system is designed to provide rapid, highly sensitive testing capability for drug discovery and high-throughput screening.
Under the agreement, with a grant from the National Institute of Aging (Bethesda, MD), Temple researchers will also screen a library of approximately 350 archived human myocardial tissue specimens with an expanded molecular target set using the assay system.
Copyright ©2002 IVD Technology
